RU2716494C2 - Способ детекции нуклеосом, содержащих гистоновые варианты - Google Patents

Способ детекции нуклеосом, содержащих гистоновые варианты Download PDF

Info

Publication number
RU2716494C2
RU2716494C2 RU2018101257A RU2018101257A RU2716494C2 RU 2716494 C2 RU2716494 C2 RU 2716494C2 RU 2018101257 A RU2018101257 A RU 2018101257A RU 2018101257 A RU2018101257 A RU 2018101257A RU 2716494 C2 RU2716494 C2 RU 2716494C2
Authority
RU
Russia
Prior art keywords
histone
nucleosome
nucleosomes
cancer
isoform
Prior art date
Application number
RU2018101257A
Other languages
English (en)
Russian (ru)
Other versions
RU2018101257A3 (https=
RU2018101257A (ru
Inventor
Якоб Винсент МИКАЛЛЕФ
Original Assignee
Белджиан Волишн Спрл
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Белджиан Волишн Спрл filed Critical Белджиан Волишн Спрл
Publication of RU2018101257A3 publication Critical patent/RU2018101257A3/ru
Publication of RU2018101257A publication Critical patent/RU2018101257A/ru
Application granted granted Critical
Publication of RU2716494C2 publication Critical patent/RU2716494C2/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/104—Lupus erythematosus [SLE]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/325—Heart failure or cardiac arrest, e.g. cardiomyopathy, congestive heart failure
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
RU2018101257A 2011-09-01 2012-08-31 Способ детекции нуклеосом, содержащих гистоновые варианты RU2716494C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161530304P 2011-09-01 2011-09-01
GB1115098.4 2011-09-01
GBGB1115098.4A GB201115098D0 (en) 2011-09-01 2011-09-01 Method for detecting nucleosomes containing histone variants
US61/530,304 2011-09-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2014112348/15A Division RU2014112348A (ru) 2011-09-01 2012-08-31 Способ детекции нуклеосом, содержащих гистоновые варианты

Publications (3)

Publication Number Publication Date
RU2018101257A3 RU2018101257A3 (https=) 2019-02-21
RU2018101257A RU2018101257A (ru) 2019-02-21
RU2716494C2 true RU2716494C2 (ru) 2020-03-12

Family

ID=44882049

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2018101257A RU2716494C2 (ru) 2011-09-01 2012-08-31 Способ детекции нуклеосом, содержащих гистоновые варианты
RU2014112348/15A RU2014112348A (ru) 2011-09-01 2012-08-31 Способ детекции нуклеосом, содержащих гистоновые варианты

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2014112348/15A RU2014112348A (ru) 2011-09-01 2012-08-31 Способ детекции нуклеосом, содержащих гистоновые варианты

Country Status (20)

Country Link
US (5) US9400276B2 (https=)
EP (2) EP3301449B1 (https=)
JP (2) JP2014529405A (https=)
KR (1) KR102130855B1 (https=)
CN (2) CN104053993A (https=)
AU (1) AU2012300643B2 (https=)
BR (1) BR112014004584B1 (https=)
CA (1) CA2845994C (https=)
DK (1) DK2751569T3 (https=)
ES (2) ES2955475T3 (https=)
GB (1) GB201115098D0 (https=)
HR (1) HRP20180362T1 (https=)
HU (1) HUE038517T2 (https=)
MX (1) MX349561B (https=)
PL (1) PL2751569T3 (https=)
PT (1) PT2751569T (https=)
RU (2) RU2716494C2 (https=)
SG (2) SG10201601168QA (https=)
WO (1) WO2013030579A1 (https=)
ZA (1) ZA201401296B (https=)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115095D0 (en) * 2011-09-01 2011-10-19 Singapore Volition Pte Ltd Method for detecting nucleosomes containing nucleotides
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants
HK1206055A1 (en) 2012-03-02 2015-12-31 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
EP2859139B1 (en) 2012-06-06 2018-08-01 The Trustees Of Princeton University Dna barcoding of designer mononucleosome and chromatin array libraries for the profiling of chromatin readers, writers, erasers, and modulators thereof
HK1216655A1 (zh) 2013-03-13 2016-11-25 Sequenom, Inc. 用於dna甲基化分析的引物
US11365447B2 (en) 2014-03-13 2022-06-21 Sequenom, Inc. Methods and processes for non-invasive assessment of genetic variations
AU2015340378B2 (en) 2014-10-29 2021-08-12 Belgian Volition Sprl Method for the enrichment of circulating tumor DNA
WO2016128383A1 (en) * 2015-02-10 2016-08-18 B.R.A.H.M.S Gmbh Free histone proteins as biomarkers
GB201511512D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell-free nucleosomes as biomarkers
GB201511542D0 (en) * 2015-07-01 2015-08-12 Singapore Volition Pte Ltd Use of cell free nucleosomes as biomarkers
GB201518674D0 (en) 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for detecting nuleosomes containing histone modifications and variants
GB201518665D0 (en) 2015-10-21 2015-12-02 Singapore Volition Pte Ltd Method for enrichment of cell free nucleosomes
GB201604806D0 (en) * 2016-03-22 2016-05-04 Singapore Volition Pte Ltd Method of identifying a cancer of unknown origin
GB201612815D0 (en) * 2016-07-25 2016-09-07 Belgian Volition Sa Novel combination test
TWI726009B (zh) * 2016-11-28 2021-05-01 比利時商比利時意志有限公司 用親和純化法分析生物樣品中源自腫瘤之無細胞核小體、分離生物樣品中純化之腫瘤dna、檢測生物樣品中源自腫瘤之核小體表觀遺傳表位或在動物或人類受試者中檢測癌症之方法或包括組蛋白h1結合劑之套組之用途
CA3049961A1 (en) 2016-12-09 2018-06-14 The Broad Institute, Inc. Crispr effector system based diagnostics
CN111108220B (zh) 2017-03-15 2024-11-19 博德研究所 用于病毒检测的基于crispr效应系统的诊断
GB201721569D0 (en) 2017-12-21 2018-02-07 Belgian Volition Sprl Method for the detection and treatment of colorectal adenomas
BR112020015093A2 (pt) 2018-01-29 2020-12-08 The Broad Institute, Inc. Diagnóstico baseado no sistema de efetor crispr
AU2019228625B2 (en) * 2018-03-01 2024-11-07 Epicypher, Inc. Quantification of nucleosome modifications using chemically-defined recombinant nucleosomes
CN119753091A (zh) 2018-04-02 2025-04-04 格里尔公司 用于扩增与癌症相关联的cfDNA分子的化验板
IL281741B2 (en) 2018-09-27 2026-04-01 Grail Inc Methylation markers and a targeted methylation detection panel
GB201818965D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Method for the detection of colorectal cancer
GB201818963D0 (en) 2018-11-21 2019-01-09 Belgian Volition Sprl Methof for the detection of prostate cancer
GB201906199D0 (en) 2019-05-02 2019-06-19 Belgian Volition Sprl Method for the detection of cancer
GB201906201D0 (en) 2019-05-02 2019-06-19 Belgian Voltion Sprl Method for the detection of protate cancer
JP2022545821A (ja) 2019-08-27 2022-10-31 ベルジアン ボリション エスアールエル 循環ヌクレオソームを単離する方法
GB201912251D0 (en) 2019-08-27 2019-10-09 Belgian Volition Sprl Method of isolating circulating nucleosomes
PL4070111T3 (pl) 2019-12-02 2025-02-03 Belgian Volition Srl Zastosowanie wolnych pozakomórkowych nukleosomsów jako biomarkerów
US20230204599A1 (en) 2020-03-20 2023-06-29 Belgian Volition SRL (BE/BE) Triaging method using cell free nucleosome levels
JP7839784B2 (ja) 2020-09-21 2026-04-02 ベルジアン ボリション エスアールエル 血液中の遊離ヌクレオソームのインラインモニタリングのための装置
TW202238131A (zh) 2020-11-25 2022-10-01 比利時商比利時意志有限公司 測量無細胞核蛋白染色質片段之方法
TW202238132A (zh) 2020-12-08 2022-10-01 比利時商比利時意志有限公司 多發性硬化症之診斷方法
TW202242145A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 核小體耗盡循環無細胞染色質片段之轉錄因子結合位點分析
TW202242130A (zh) 2020-12-29 2022-11-01 比利時商比利時意志有限公司 循環轉錄因子分析
TW202242146A (zh) 2021-01-13 2022-11-01 比利時商比利時意志有限公司 肺癌的檢測方法
GB202108185D0 (en) 2021-06-08 2021-07-21 Belgian Volition Sprl Standardisation of nucleosome assays using biologically derived calibrants
GB202108452D0 (en) 2021-06-14 2021-07-28 Belgian Volition Sprl Triaging method using cell free nucleosome levels
EP4423501A1 (en) 2021-10-29 2024-09-04 Belgian Volition SRL Homogeneous immunoassay method
GB202117799D0 (en) 2021-12-09 2022-01-26 Belgian Volition Srl Method for the detection of blood cancer
WO2023170298A1 (en) 2022-03-11 2023-09-14 Belgian Volition Srl Differential diagnosis method
GB202205212D0 (en) 2022-04-08 2022-05-25 Belgian Volition Sprl Method for transplant organ health assessment
WO2024042210A1 (en) 2022-08-25 2024-02-29 Belgian Volition Srl Method for measuring cell free chromatin
IL319155A (en) 2022-08-25 2025-04-01 Belgian Volition Srl A method for detecting dementia
EP4639173A1 (en) 2022-12-19 2025-10-29 Belgian Volition SRL Calibration
EP4639165A1 (en) 2022-12-19 2025-10-29 Belgian Volition SRL Assessment of biological samples for nucleic acid analysis
GB202300607D0 (en) 2023-01-16 2023-03-01 Belgian Volition Srl Proteins and methods for isolating circulating nucleosomes
GB202303562D0 (en) 2023-03-10 2023-04-26 Belgian Volition Sprl Sample collection for liquid biopsy
WO2024213795A1 (en) 2023-04-14 2024-10-17 Belgian Volition Srl Diagnosis method using cell free nucleosome levels
WO2024223947A1 (en) 2023-04-28 2024-10-31 Belgian Volition Srl Use of cell free nucleosomes as biomarkers of carcinomas
GB202307768D0 (en) 2023-05-24 2023-07-05 Belgian Volition Srl Use of cell free nucleosomes as biomarkers
GB202310137D0 (en) 2023-07-03 2023-08-16 Belgian Volition Srl Method for the detection of cancer
WO2025012440A1 (en) 2023-07-13 2025-01-16 Belgian Volition Srl Method for detection of the potential of a body fluid sample to produce extracellular traps
WO2025061853A1 (en) 2023-09-19 2025-03-27 Belgian Volition Srl Lateral flow test device
WO2025093747A1 (en) 2023-11-02 2025-05-08 Belgian Volition Srl Novel rapid high-throughput method of netosis induction and inhibition with physiologically relevant molecules
WO2025181348A1 (en) 2024-03-01 2025-09-04 Belgian Volition Srl Method for determining the origin of circulating dna
WO2025253002A1 (en) 2024-06-07 2025-12-11 Belgian Volition Srl Sample collection for liquid biopsy
WO2026052765A1 (en) 2024-09-05 2026-03-12 Belgian Volition Srl Method using nucleosome levels

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019826A1 (en) * 2003-08-18 2005-03-03 Chroma Therapeutics Limited Detection of histone modification in cell-free nucleosomes
WO2011000573A1 (en) * 2009-07-02 2011-01-06 Embl European Molecular Biology Laboratory Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002238994A1 (en) * 2001-03-23 2002-10-08 Center For Advanced Science And Technology Incubation, Ltd. Mononucleosome and process for producing the same, method of assaying antibody specific to nucleosome, method of diagnosing autoimmune disease, process for producing nucleosome dna, dna plate, process for producing dna plate and method of assaying anti-dna antibody
EP1411975A4 (en) * 2001-07-03 2005-04-27 Univ Virginia METHYLATION OF HISTON H4 AT ARGININE 3
DE10207735A1 (de) * 2002-02-15 2003-08-28 Euroimmun Gmbh Verfahren zur Herstellung einer Nukleosomen-Präparation und deren Verwendung zur in vitro-Diagnose von Lupus erythematodes disseminatus (LED)
AU2003216291A1 (en) 2002-02-20 2003-09-09 Chroma Therapeutics Ltd. A non-invasive diagnostic test utilizing histone modification markers
WO2005040814A1 (en) * 2003-10-14 2005-05-06 Cancer Research Technology Limited Methods and means of cancer detection by histone modification
EP1907856A2 (en) * 2005-07-27 2008-04-09 Oncomethylome Sciences SA Angiogenesis inhibition based upon icam 1 or junb expression levels
US20080318264A1 (en) * 2005-09-09 2008-12-25 University Of Iowa Research Foundation Biomarkers Associated With Age-Related Macular Degeneration
WO2010033658A2 (en) * 2008-09-17 2010-03-25 The Rockefeller University Cathepsin l proteolytically processes histone h3 during mouse embroyonic stem cell differentiation
GB201115098D0 (en) 2011-09-01 2011-10-19 Belgian Volition Sa Method for detecting nucleosomes containing histone variants

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005019826A1 (en) * 2003-08-18 2005-03-03 Chroma Therapeutics Limited Detection of histone modification in cell-free nucleosomes
WO2011000573A1 (en) * 2009-07-02 2011-01-06 Embl European Molecular Biology Laboratory Diagnostic method for predicting the risk of cancer recurrence based on histone macroh2a isoforms

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DELIGESER U. et al. Sequence-Specific Histone Methylation Is Detectable on Circulating Nucleosomes in Plasma. Clinical Chemistry. 2008; 54(7): 1125-1131 [Найдено 07.09.2018] [он-лайн]. Найдено из Интернет: URL: http://www.clinchem.org/content/54/7/1125.full . *
DELIGESER U. et al. Sequence-Specific Histone Methylation Is Detectable on Circulating Nucleosomes in Plasma. Clinical Chemistry. 2008; 54(7): 1125-1131 [Найдено 07.09.2018] [он-лайн]. Найдено из Интернет: URL: http://www.clinchem.org/content/54/7/1125.full . ВЕЙКО Н.Н. и др. Фрагменты транскрибируемой области рибосомного повтора в составе внеклеточной ДНК - маркер гибели клеток организма. Биомедицинская химия. 2008; 54(1): 78-93. EKBOM A. et al. Increased risk of both ulcerative colitis and Crohns disease in a population suffering from COPD. Lung. 2008 May-Jun; 186(3): 167-172. *
EKBOM A. et al. Increased risk of both ulcerative colitis and Crohns disease in a population suffering from COPD. Lung. 2008 May-Jun; 186(3): 167-172. *
ВЕЙКО Н.Н. и др. Фрагменты транскрибируемой области рибосомного повтора в составе внеклеточной ДНК - маркер гибели клеток организма. Биомедицинская химия. 2008; 54(1): 78-93. *

Also Published As

Publication number Publication date
CA2845994C (en) 2020-10-13
ES2662380T3 (es) 2018-04-06
MX2014002444A (es) 2014-10-23
DK2751569T3 (en) 2018-03-12
SG11201400202SA (en) 2014-03-28
US9400276B2 (en) 2016-07-26
PT2751569T (pt) 2018-03-28
CN108107215A (zh) 2018-06-01
KR20140078638A (ko) 2014-06-25
KR102130855B1 (ko) 2020-07-09
JP6494703B2 (ja) 2019-04-03
BR112014004584B1 (pt) 2021-07-06
US20140206014A1 (en) 2014-07-24
AU2012300643B2 (en) 2017-06-15
EP2751569A1 (en) 2014-07-09
HRP20180362T1 (hr) 2018-06-01
EP2751569B1 (en) 2017-12-27
AU2012300643A1 (en) 2014-03-06
CA2845994A1 (en) 2013-03-07
EP3301449B1 (en) 2023-08-09
SG10201601168QA (en) 2016-03-30
HK1253354A1 (en) 2019-06-14
EP3301449C0 (en) 2023-08-09
MX349561B (es) 2017-08-02
RU2014112348A (ru) 2015-10-10
EP3301449A1 (en) 2018-04-04
CN104053993A (zh) 2014-09-17
PL2751569T3 (pl) 2018-06-29
GB201115098D0 (en) 2011-10-19
HK1199758A1 (en) 2015-07-17
US20190120853A1 (en) 2019-04-25
RU2018101257A3 (https=) 2019-02-21
RU2018101257A (ru) 2019-02-21
JP2017215338A (ja) 2017-12-07
ZA201401296B (en) 2014-12-23
HUE038517T2 (hu) 2018-10-29
ES2955475T3 (es) 2023-12-01
US20160299152A1 (en) 2016-10-13
US20230116530A1 (en) 2023-04-13
WO2013030579A1 (en) 2013-03-07
BR112014004584A2 (pt) 2017-05-16
JP2014529405A (ja) 2014-11-13
US10184945B2 (en) 2019-01-22
US20200341006A1 (en) 2020-10-29

Similar Documents

Publication Publication Date Title
RU2716494C2 (ru) Способ детекции нуклеосом, содержащих гистоновые варианты
RU2687483C2 (ru) Способ детекции нуклеосом, содержащих нуклеотиды
US9222937B2 (en) Method for detecting nucleosomes
US20170003296A1 (en) Method for detecting histone modifications in nucleosomes
HK40008468A (en) Method for detecting nucleosomes containing nucleotides
HK1199758B (en) Method for detecting nucleosomes containing histone variants
HK1199760B (en) Method for detecting nucleosomes containing nucleotides
HK1199761B (en) Method for detecting nucleosomes